BioCentury | Mar 3, 2014
Company News

Poniard, Verastem deal

...Verastem acquired VS-4718 from Poniard and is now the direct licensee of the compound from The...
...now the direct licensee of the compound from The Scripps Research Institute (La Jolla, Calif.). Poniard...
...eligible for up to $3 million in milestones, plus a low single-digit royalty. In 2011, Poniard...
BioCentury | Sep 30, 2013
Strategy

FAKs of life

...The biotech also had VS-4718 , a preclinical focal adhesion kinase (FAK) inhibitor licensed from Poniard Pharmaceuticals Inc....
...Ind. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Pfizer Inc. (NYSE:PFE), New York, N.Y. Poniard Pharmaceuticals Inc....
BioCentury | Jul 1, 2013
Clinical News

VS-4718: Phase I started

...worldwide rights from Poniard to 2 FAK inhibitors, including VS-4718 (see BioCentury, Dec. 5, 2011). Poniard Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Company News

NeoRx other research news

...gene for the protein was incorporated into corn, with purified antibody produced by NSC Technologies. NeoRx...
BioCentury | Apr 11, 2013
Distillery Therapeutics

Indication: Cancer

...in Phase I testing to treat ovarian cancer. Verastem's VS-4718, a FAK inhibitor in-licensed from Poniard Pharmaceuticals Inc....
BioCentury | Nov 19, 2012
Clinical News

Poniard, Verastem preclinical data

...worldwide rights from Poniard to 2 FAK inhibitors, including VS-4718 (see BioCentury, Dec. 5, 2011). Poniard Pharmaceuticals Inc....
BioCentury | Sep 17, 2012
Company News

Tobira management update

...Francisco, Calif. Business: Infectious Hired: Caroline Loewy as EVP and CFO, formerly acting CEO of Poniard Pharmaceuticals Inc. WIR...
BioCentury | Jul 16, 2012
Company News

Verastem, S*BIO, Eisai, Pfizer deal

...testing in mid-2013 for advanced solid tumors. Last year, Verastem received exclusive, worldwide rights from Poniard Pharmaceuticals Inc....
BioCentury | Jul 12, 2012
Company News

Verastem in-licenses Pfizer's FAK inhibitor

...market close, was up $0.32 on Wednesday. Last year, Verastem received exclusive, worldwide rights from Poniard Pharmaceuticals Inc....
BioCentury | Jan 9, 2012
Company News

Poniard cancer news

...McMahon who is resigning along with directors E. Rolland Dickson, Gary Lyons and Nicholas Simon. Poniard...
...committee of the board, chaired by Fred Craves, will lead the company's management team. Additionally, Poniard...
...plans to list on the OTC Bulletin Board. Last month, Allozyne Inc. (Seattle, Wash.) and Poniard...
Items per page:
1 - 10 of 337
BioCentury | Mar 3, 2014
Company News

Poniard, Verastem deal

...Verastem acquired VS-4718 from Poniard and is now the direct licensee of the compound from The...
...now the direct licensee of the compound from The Scripps Research Institute (La Jolla, Calif.). Poniard...
...eligible for up to $3 million in milestones, plus a low single-digit royalty. In 2011, Poniard...
BioCentury | Sep 30, 2013
Strategy

FAKs of life

...The biotech also had VS-4718 , a preclinical focal adhesion kinase (FAK) inhibitor licensed from Poniard Pharmaceuticals Inc....
...Ind. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Pfizer Inc. (NYSE:PFE), New York, N.Y. Poniard Pharmaceuticals Inc....
BioCentury | Jul 1, 2013
Clinical News

VS-4718: Phase I started

...worldwide rights from Poniard to 2 FAK inhibitors, including VS-4718 (see BioCentury, Dec. 5, 2011). Poniard Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Company News

NeoRx other research news

...gene for the protein was incorporated into corn, with purified antibody produced by NSC Technologies. NeoRx...
BioCentury | Apr 11, 2013
Distillery Therapeutics

Indication: Cancer

...in Phase I testing to treat ovarian cancer. Verastem's VS-4718, a FAK inhibitor in-licensed from Poniard Pharmaceuticals Inc....
BioCentury | Nov 19, 2012
Clinical News

Poniard, Verastem preclinical data

...worldwide rights from Poniard to 2 FAK inhibitors, including VS-4718 (see BioCentury, Dec. 5, 2011). Poniard Pharmaceuticals Inc....
BioCentury | Sep 17, 2012
Company News

Tobira management update

...Francisco, Calif. Business: Infectious Hired: Caroline Loewy as EVP and CFO, formerly acting CEO of Poniard Pharmaceuticals Inc. WIR...
BioCentury | Jul 16, 2012
Company News

Verastem, S*BIO, Eisai, Pfizer deal

...testing in mid-2013 for advanced solid tumors. Last year, Verastem received exclusive, worldwide rights from Poniard Pharmaceuticals Inc....
BioCentury | Jul 12, 2012
Company News

Verastem in-licenses Pfizer's FAK inhibitor

...market close, was up $0.32 on Wednesday. Last year, Verastem received exclusive, worldwide rights from Poniard Pharmaceuticals Inc....
BioCentury | Jan 9, 2012
Company News

Poniard cancer news

...McMahon who is resigning along with directors E. Rolland Dickson, Gary Lyons and Nicholas Simon. Poniard...
...committee of the board, chaired by Fred Craves, will lead the company's management team. Additionally, Poniard...
...plans to list on the OTC Bulletin Board. Last month, Allozyne Inc. (Seattle, Wash.) and Poniard...
Items per page:
1 - 10 of 337